In Alcoholic fatty liver disease VIBOLIV 300 MG INJECTION belongs to a class of drugs known as hepatoprotectives. It fastens clearance of alcohol from the blood and therefore helps in the treatment of fatty liver due to alcoholism. In the long term, it protects the liver from damage against harmful chemicals known as free radicals, thereby improving the overall health of the liver. It is given as an injection by your doctor or healthcare provider. Take it in the dose and duration advised by the doctor. To make the medicine more effective and for general health benefits, stop smoking, maintain a healthy weight, and do not drink too much alcohol.
It is not known whether it is safe to consume alcohol with VIBOLIV 300 MG INJECTION. Please consult your doctor.
VIBOLIV 300 MG INJECTION may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Information regarding the use of VIBOLIV 300 MG INJECTION during breastfeeding is not available. Please consult your doctor.
It is not known whether VIBOLIV 300 MG INJECTION alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
There is limited information available on the use of VIBOLIV 300 MG INJECTION in patients with kidney disease. Please consult your doctor.
There is limited information available on the use of VIBOLIV 300 MG INJECTION in patients with liver disease. Please consult your doctor.
If you miss a dose of VIBOLIV 300 MG INJECTION, skip it and continue with your normal schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Micro Labs Ltd || ₹14.5/tablet (25% cheaper)